Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENTINEL-101: CLSP-5282 in Solid Tumors with KRas G12V Mutation
NCT07650357Phase 1Not yet recruiting
- Sponsor
- Clasp Therapeutics
- Start
- Jul 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of CLSP-5282 in solid tumor, non-small cell lung cancer (NSCLC), pancreatic cancer (PC) and 1 more (2 arms), sponsored by Clasp Therapeutics. Primary endpoints: Maximum Tolerated Dose and/or Recommended Dose for Expansion at 28 days and Preliminary Antitumor Activity up to 24 months. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
CLSP-5282
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)pancreatic cancer (PC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07650357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07650357.